Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cyclosporin eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Excimer Laser Trabeculotomy (ELT) for glaucomaStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over (TA1093)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 August 2025
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 3 September 2026
Monofocal intraocular lenses for cataract surgery (provisional title)Status:In developmentProgramme:Health technology evaluationExpected publication date: TBC
Pegcetacoplan for treating geographic atrophy [ID4041]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 March 2026
Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]Status:Awaiting development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 8 January 2026Expected publication date: TBC
Satralizumab for treating thyroid eye disease [ID6648]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Teprotumumab for treating thyroid eye disease [ID6432]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vamikibart for treating uveitic macular oedema [ID6671]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Veligrotug for treating thyroid eye disease [ID6636]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC